Evidence map›Paper›PMID 31129149›Full record

ArticleCancer letters2019

Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway.

Kaitlin C Fogg, Will R Olson, Jamison N Miller, Aisha Khan, Carine Renner, Isaac Hale, Paul S Weisman, Pamela K Kreeger

Open access · greenAbstract read
In one paragraph

Article in Cancer letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Review
  3. Cross-assay RNA modeling reveals cancer biomarkers.bioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kaitlin C FoggDepartment of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA.
Will R OlsonDepartment of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA.
Jamison N MillerDepartment of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA.
Aisha KhanDepartment of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA.
Carine RennerDepartment of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA.
Isaac HaleDepartment of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA.
Paul S WeismanDepartment of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Pamela K KreegerDepartment of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA; University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address: kreeger@wisc.edu.
University of Wisconsin–Madison · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Engineered ECM platforms to analyze progression in high grade serous ovarian cancerR01CA232517 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CAMPAGNOLA, PAUL J, KREEGER, PAMELA K · 2018 to 2022
$2.4M
Analysis of how quantitative cellular network variation impacts tumor progressionDP2CA195766 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KREEGER, PAMELA K · 2014 to 2014
$2.3M
NCI NIH HHS DP2 CA195766NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA232517
6 · The paper itself

Abstract

High-grade serous ovarian cancer (HGSOC) metastasizes when tumor spheroids detach from the primary tumor and re-attach throughout the peritoneal cavity. Once the cancer cells have implanted in these new sites, the development of metastatic lesions is dependent on the disaggregation of cancer cells from the spheroids and subsequent expansion across the collagenous extracellular matrix (ECM). As HGSOC progresses an increase in alternatively activated macrophages (AAMs) in the surrounding ascites fluid has been observed and AAMs have been shown to enhance tumor invasion and growth in a wide range of cancers. We hypothesized that soluble factors from AAMs in the peritoneal microenvironment promote the disaggregation of ovarian cancer spheroids across the underlying ECM. We determined that co-culture with AAMs significantly increased HGSOC spheroid spreading across a collagen matrix. Multivariate modeling identified AAM-derived factors that correlated with enhanced spread of HGSOC spheroids and experimental validation showed that each individual cell line responded to a distinct AAM-derived factor (FLT3L, leptin, or HB-EGF). Despite this ligand-level heterogeneity, we determined that the AAM-derived factors utilized a common signaling pathway to induce spheroid spreading: JAK2/STAT3 activation followed by MMP-9 mediated spreading. Furthermore, immunostaining demonstrated that FLT3, LEPR, EGFR, and pSTAT3 were upregulated in metastases in HGSOC patients, with substantial patient-to-patient heterogeneity. These results suggest that inhibiting individual soluble factors will not inhibit AAM-induced effects across a broad group of patients; instead, the downstream JAK2/STAT3/MMP-9 pathway should be examined as potential therapeutic targets to slow metastasis in ovarian cancer.

Indexed as

AdolescentAdultCell Line, TumorCystadenocarcinoma, SerousFemalefms-Like Tyrosine Kinase 3HumansJanus Kinase 2Macrophage ActivationMacrophagesMatrix Metalloproteinase 9Middle AgedNeoplasm MetastasisOvarian NeoplasmsReceptors, LeptinSignal TransductionFLT3 protein, humanfms-Like Tyrosine Kinase 3JAK2 protein, humanJanus Kinase 2LEPR protein, humanMatrix Metalloproteinase 9MMP9 protein, humanReceptors, LeptinSTAT3 protein, humanSTAT3 Transcription FactorMacrophagesMMP-9Ovarian cancerSTAT3Tumor microenvironment

Identifiers

PMID31129149
PMCPMC6659112
OpenAlexW2945388820

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.